Search

Displaying results 1211 - 1220 of 7604 in total
  1. Drug

    Mirikizumab

    go.drugbank.com/drugs/DB14910
    ApprovedInvestigational

    Mirikizumab is a monoclonal antibody developed by Eli Lilly intended to treat ulcerative colitis. … [L46237] In April 2023, the US FDA declined to approve mirikizumab for the treatment of ulcerative colitis on the basis of manufacturing concerns.

  2. Drug

    Pralsetinib

    go.drugbank.com/drugs/DB15822
    ApprovedInvestigational

    It is currently marketed under the brand name GAVRETO™ by Blueprint Medicines.[L15986] … of metastatic RET-fusion positive non-small cell lung cancer.

  3. Drug

    Cholestyramine

    go.drugbank.com/drugs/DB01432
    ApprovedInvestigational

    Cholestyramine resin is quite hydrophilic, but insoluble in water.

    Categories: Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia
  4. Drug

    Deflazacort

    go.drugbank.com/drugs/DB11921
    Approved

    [A179446,A179449,L6697] This disease usually manifests by muscle weakness in early childhood followed by loss of the ability to walk (ambulation) as early as age 7. … It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.

  5. Drug

    Eteplirsen

    go.drugbank.com/drugs/DB06014
    ApprovedInvestigational

    Eteplirsen directly works on the DMD gene to promote dystrophin production. Eteplirsen was the first treatment for DMD approved by the FDA.[A244925] … [L40015] Duchenne muscular dystrophy is a rare genetic disorder characterized by progressive muscle deterioration and premature death most commonly due to respiratory or cardiac complications.

    Synonyms: N-dimethylphosphonamidate) RNA, dimethylamino)](2',3'-dideoxy-2',3'-imino-2',3'-seco)(2'a→5')(C-m5U-C-C-A-A-C-A-m5U-C-A-A-G-G-A-A-G-A-m5U-G-G-C-A-m5U-m5U-m5U-C-m5U-A-G),5'-(P-(4-((2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)carbonyl)-1-piperazinyl)-N,
  6. Drug

    Ruxolitinib

    go.drugbank.com/drugs/DB08877
    ApprovedInvestigational

    By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. … [A229883] Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation.

  7. Drug

    Vorapaxar

    go.drugbank.com/drugs/DB09030
    Approved

    By inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation.

    Synonyms: Carbamic acid, N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(E)-2-[5-(3-fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-, ethyl ester, Ethyl N-[(3R,3aS,4S,4aR,7R,8aR,9aR)-4-[(E)-2-[5-(3-fluorophenyl)-2-pyridyl]vinyl]-3-methyl-1-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3H-benzo[f]isobenzofuran-7-yl]carbamate
  8. Drug

    Human Rho(D) immune globulin

    go.drugbank.com/drugs/DB11597
    Approved

    Human Rho(D) immune globulin is a medicine given by intramuscular or intravenous injection that is used to prevent the immunological condition known as Rh disease (or hemolytic disease of newborn). … It was approved by FDA as treatment for suppression of rhesus (Rh) isoimmunization or chronic immune thrombocytopenic purpura (ITP) in adults.

  9. Drug

    Dextrothyroxine

    go.drugbank.com/drugs/DB00509
    ApprovedWithdrawn

    Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. … Thyroxine is peripherally deiodinated to form triiodothyronine which exerts a broad spectrum of stimulatory effects on cell metabolism.

    Synonyms: O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-D-tyrosine
  10. Drug

    Cefuroxime

    go.drugbank.com/drugs/DB01112
    ApprovedInvestigational

    Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus.

    Products: Nu-cefuroxime